Sarepta Therapeutics (SRPT) Insider Trading & Ownership $74.10 +0.65 (+0.88%) Closing price 03/21/2025 04:00 PM EasternExtended Trading$74.04 -0.05 (-0.07%) As of 03/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Sarepta Therapeutics (NASDAQ:SRPT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.70%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$4.96 MNumber OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$10.67 M Get SRPT Insider Trade Alerts Want to know when executives and insiders are buying or selling Sarepta Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SRPT Insider Buying and Selling by Quarter Remove Ads Sarepta Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/12/2025Claude NicaiseDirectorSell2,491$99.64$248,203.24 12/12/2024Hans Lennart Rudolf WigzellDirectorSell10,500$124.84$1,310,820.00 12/5/2024Kathryn Jean BoorDirectorSell1,636$125.55$205,399.80 8/30/2024Ian Michael EstepanCFOSell5,985$137.36$822,099.60 8/16/2024Michael Andrew ChambersDirectorBuy37,038$133.80$4,955,684.40 6/25/2024Ryan Edward BrownEVPSell38,957$161.61$6,295,840.77 6/24/2024Bilal ArifInsiderSell7,859$163.08$1,281,645.72 5/2/2024Dallan MurrayInsiderSell3,635$140.00$508,900.00 (Data available from 1/1/2013 forward) SRPT Insider Trading Activity - Frequently Asked Questions Who is on Sarepta Therapeutics's Insider Roster? The list of insiders at Sarepta Therapeutics includes Bilal Arif, Claude Nicaise, Dallan Murray, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Ian Michael Estepan, Kathryn Jean Boor, Michael Andrew Chambers, Richard Barry, Ryan Edward Brown, and Stephen Mayo. Learn more on insiders at SRPT. What percentage of Sarepta Therapeutics stock is owned by insiders? 7.70% of Sarepta Therapeutics stock is owned by insiders. Learn more on SRPT's insider holdings. Which Sarepta Therapeutics insiders have been buying company stock? The following insiders have purchased SRPT shares in the last 24 months: Douglas S Ingram ($2,001,856.00), Michael Andrew Chambers ($9,749,217.58), and Richard Barry ($3,940,500.00). How much insider buying is happening at Sarepta Therapeutics? Insiders have purchased a total of 157,109 SRPT shares in the last 24 months for a total of $15,691,573.58 bought. Which Sarepta Therapeutics insiders have been selling company stock? The following insiders have sold SRPT shares in the last 24 months: Bilal Arif ($1,539,325.72), Claude Nicaise ($248,203.24), Dallan Murray ($508,900.00), Hans Lennart Rudolf Wigzell ($4,760,370.00), Ian Michael Estepan ($976,059.60), Kathryn Jean Boor ($298,949.53), Ryan Edward Brown ($6,295,840.77), and Stephen Mayo ($385,479.60). How much insider selling is happening at Sarepta Therapeutics? Insiders have sold a total of 108,159 Sarepta Therapeutics shares in the last 24 months for a total of $15,013,128.46 sold. Sarepta Therapeutics Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Compensation: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Compensation: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Compensation: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Compensation: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of Staff More Insider Trading Tools from MarketBeat Related Companies argenx Insider Buying Beigene Insider Buying BioNTech Insider Buying Teva Pharmaceutical Industries Insider Buying Summit Therapeutics Insider Buying Intra-Cellular Therapies Insider Buying Genmab A/S Insider Buying Moderna Insider Buying Viatris Insider Buying Vaxcyte Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It MattersInsider Scoop: 4 Stocks Insiders Are Buying and Selling2 Stocks Insiders Are Buying and 1 They're Selling This page (NASDAQ:SRPT) was last updated on 3/23/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.